Oncotype DX Breast Recurrence Score®

The Oncotype DX test provides significant value in clinical practice

For node-positive, early breast cancer patients

The Oncotype DX Breast Recurrence Score result is predictive of chemotherapy benefit in your patients with HR+, HER2-, node-positive (1-3 positive nodes), early-stage, invasive breast cancer.1 Data from comprehensive research show that a substantial proportion of these patients may be safely spared chemotherapy1-4,9

How does the Oncotype DX test guide treatment decisions?
  • Patients with Recurrence Score results 0–17 did not benefit from the addition of chemotherapy to endocrine therapy in the SWOG-8814 randomised clinical study.1 Real-world studies confirmed positive clinical outcomes in N1 patients with Recurrence Score results 0–17 on endocrine therapy alone.2,3
  • Patients with Recurrence Score results 31–100 derived on average a 19% absolute benefit from the addition of chemotherapy to endocrine therapy.1
How does the Oncotype DX test reduce the risk of overtreatment?

A significant proportion of patients have tumours with low Recurrence Score results across N0, N1mi, and N+ populations4

Nodal status, despite being prognostic, does not predict the Recurrence Score result4

Overall, 610,350 tumor specimens were examined by the Genomic Health laboratory from February 2004 to August 20174

The Oncotype DX test reduces the risk of overtreatment

A large pro­portion

of node positive patients tested in real world with the Oncotype DX test have a Recurrence Score result 0-17 and may be overtreated without testing
N1
Nodal status, despite being of prognostic value, does not predict underlying tumor biology/chemosensitivity

The Oncotype DX Breast Recurrence Score* test should be used for:

  • All patients for whom chemotherapy can potentially be spared
  • All patients for whom chemotherapy can potentially be life-saving

*For early stage, HR+, HER2- patients with up to 3 nodes involved

ABBREVIATIONS

CT=chemotherapy;
HER2–=human epidermal growth factor receptor 2 negative;
HR+=hormone receptor positive;
LN=lymph node;
N+=node-positive;
N0=node-negative;
N1mi=node-positive + micrometastases;
N1=1–3 positive nodes;
RS=Recurrence Score result

REFERENCES
  1. Albain et al. Lancet Oncol. 2010.
  2. Stemmer et al. NPJ Breast Cancer. 2017.
  3. Hortobagyi et al. SABCS. 2018.
  4. Bello et al. Ann Surg Onc. 2018.
  5. NICE 2018. Available at: www.nice.org.uk/guidance/dg34.
  6. Sparano and Paik. J Clin Oncol. 2008.
  7. Sparano et al. N Engl J Med. 2015.
  8. Sparano et al. N Engl J Med. 2018.
  9. Nitz et al. Breast Cancer Res Treat. 2017.

Contact Us

Get in Touch
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.